a developer of novel antibody therapeutics for oncology targets
Industry Biotechnology
A.I.dvisor indicates that over the last year, YMAB has been loosely correlated with RIGL. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if YMAB jumps, then RIGL could also see price increases.
Ticker / NAME | Correlation To YMAB | 1D Price Change % | ||
---|---|---|---|---|
YMAB | 100% | -3.00% | ||
RIGL - YMAB | 35% Loosely correlated | -2.38% | ||
MDXG - YMAB | 35% Loosely correlated | -6.73% | ||
VERA - YMAB | 34% Loosely correlated | +1.43% | ||
XNCR - YMAB | 34% Loosely correlated | -3.14% | ||
KROS - YMAB | 34% Loosely correlated | +5.38% | ||
More |
Ticker / NAME | Correlation To YMAB | 1D Price Change % |
---|---|---|
YMAB | 100% | -3.00% |
pharmaceuticals theme (167 stocks) | 37% Loosely correlated | +0.82% |
oncology theme (18 stocks) | 34% Loosely correlated | +0.37% |
antibody theme (6 stocks) | 28% Poorly correlated | +3.08% |